NCT06223230 Nutritional Psychological Intervention and Vomit-free Management on Survival and Quality of Life in Advanced Gastrointestinal Tumors
| NCT ID | NCT06223230 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Renmin Hospital of Wuhan University |
| Condition | Digestive System Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 316 participants |
| Start Date | 2022-06-01 |
| Primary Completion | 2025-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 316 participants in total. It began in 2022-06-01 with a primary completion date of 2025-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Aims to observe and evaluate the impact of survival and quality of life of patients with gastrointestinal tumors such as advanced esophageal, gastric, liver, pancreatic, and colorectal cancers through nutritional-psychological interventions versus no-vomit management compared to standard antitumor therapy alone
Eligibility Criteria
Inclusion Criteria: 1. Age 18-75, male or female; 2. Patients with advanced esophageal cancer, gastric cancer, liver cancer and colorectal cancer and other gastrointestinal tumors diagnosed by pathological histology or cytology; 3. Expected survival ³ 8 weeks and able to receive long-term follow-up; 4. Eastern Cooperative Oncology Group(ECOG)-Performance Status(PS) score of 0-2; 5. First-line treatment receiving standard oncology treatment and nutritional psychological intervention and vomit-free management group (study group); first-line treatment receiving only standard oncology treatment group (control group); 6. Voluntarily signing an informed consent form. Exclusion Criteria: 1. Other malignant tumors diagnosed within the previous 5 years, except for effectively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or effectively resected in situ cervical cancer or breast cancer; 2. history of psychiatric illness prior to the diagnosis of the tumor 3. patients who resist treatment 4. patients with poorly controlled severe heart disease, liver or kidney insufficiency, severe anemia, multiple lymph node enlargement, leukopenia, etc; 5. patients who are pregnant or have a pregnancy plan; 6. patients who, in the judgment of the investigator, are not suitable for inclusion in this study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06223230 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Digestive System Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06223230 currently recruiting?
Yes, NCT06223230 is actively recruiting participants. Contact the research team at yongshun2007@163.com for enrollment information.
Where is the NCT06223230 trial being conducted?
This trial is being conducted at Wuhan, China.
Who is sponsoring the NCT06223230 clinical trial?
NCT06223230 is sponsored by Renmin Hospital of Wuhan University. The trial plans to enroll 316 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.